Merck: oncology trial with Korea's GI Innovation
(CercleFinance.com) - South Korean biotech GI Innovation announced on Monday that it had signed an agreement with Merck to conduct a Phase II clinical trial in oncology.
The study aims to evaluate the safety and efficacy of the combination of its GI-102 and Keytruda, Merck's flagship immunotherapy, in the treatment of patients with liver cancer, melanoma and kidney cancer hitherto resistant to immunotherapies.
GI Innovation says that its GI-102 monotherapy has previously shown a partial response rate of 42.9% in the treatment of melanoma, i.e. a response in three out of seven patients.
In preclinical trials, the complete response rate in mice had reached 60% with GI-102 in mice treated for liver cancer.
This is the second partnership between Merck and GI Innovation, following an initial collaboration on GI-101A.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The study aims to evaluate the safety and efficacy of the combination of its GI-102 and Keytruda, Merck's flagship immunotherapy, in the treatment of patients with liver cancer, melanoma and kidney cancer hitherto resistant to immunotherapies.
GI Innovation says that its GI-102 monotherapy has previously shown a partial response rate of 42.9% in the treatment of melanoma, i.e. a response in three out of seven patients.
In preclinical trials, the complete response rate in mice had reached 60% with GI-102 in mice treated for liver cancer.
This is the second partnership between Merck and GI Innovation, following an initial collaboration on GI-101A.
Copyright (c) 2024 CercleFinance.com. All rights reserved.